Treatment of Moderna Vaccine-Related Pericarditis
For pericarditis following Moderna COVID-19 vaccination, treat with NSAIDs, colchicine, and/or prednisone as first-line therapy, following the same approach used for COVID-19 infection-related pericarditis 1.
Initial Evaluation
When a patient presents with chest pain after Moderna vaccination, obtain:
- ECG (looking for diffuse ST elevation, PR depression)
- High-sensitivity cardiac troponin (to distinguish pure pericarditis from myopericarditis)
- Echocardiogram (to assess for pericardial effusion and ventricular function)
- SARS-CoV-2 PCR testing (to exclude concurrent infection) 1
Obtain cardiology consultation if troponin is rising or if ECG/echo shows concerning abnormalities 1.
Treatment Algorithm
For Mild-to-Moderate Pericarditis (Normal Troponin, Normal LVEF)
First-line therapy:
- NSAIDs (ibuprofen 600-800 mg TID or aspirin 750-1000 mg TID) for chest pain and inflammation 1
- Colchicine 0.5-0.6 mg daily (or BID if >70 kg) 1, 2
- Continue for 2-4 weeks, then taper based on symptom resolution and inflammatory markers
If symptoms persist despite NSAIDs and colchicine:
- Add prednisone 0.25-0.5 mg/kg/day 1
- Taper gradually over several weeks based on clinical response
For Myopericarditis (Elevated Troponin with Pericardial Features)
Hospitalize for monitoring if:
- Elevated troponin
- Abnormal ECG or echo findings
- Concerning arrhythmias
- Any hemodynamic instability 1
Treatment approach:
- If rapidly improving with normal/improving troponin and normal LVEF: anti-inflammatory medications may not be needed 1
- If ongoing symptoms: use NSAIDs, colchicine, and corticosteroids as above 1
For Refractory or Recurrent Cases
If inadequate response to first-line therapy:
- Escalate to corticosteroids (all patients in one case series required this) 3
- For difficult-to-treat recurrent pericarditis: consider IL-1 blockade with rilonacept or anakinra 3, 4
- Anakinra has shown rapid resolution (within 72 hours) of large pericardial effusions in vaccine-related cases 4
Activity Restriction
Avoid strenuous physical activity for 3-6 months after diagnosis 1. This applies regardless of whether the diagnosis is pure pericarditis or myopericarditis.
Follow-Up Monitoring
Reassess at 3-6 months with:
- ECG
- Echocardiogram
- Consider cardiac MRI if initial presentation included myocardial involvement 1
Monitor for:
- Resolution of symptoms
- Normalization of inflammatory markers
- Recovery of any ventricular dysfunction
Critical Pitfalls to Avoid
Don't miss myocardial involvement: Always check troponin—elevated levels change the diagnosis from pericarditis to myopericarditis, requiring hospitalization and closer monitoring 1
Don't discharge too quickly: Even mild cases warrant observation if troponin is elevated or arrhythmias are present 1
Don't use beta-blockers prematurely: In myopericarditis with reduced LVEF, beta-blockers can precipitate cardiogenic shock 1
Don't ignore recurrence: Some cases develop difficult-to-treat recurrent pericarditis requiring IL-1 blockade; early recognition and escalation prevent complications 3
Future Vaccination Considerations
Do not administer additional doses of any COVID-19 vaccine to patients who developed pericarditis or myopericarditis after mRNA vaccination, per CDC guidelines 1. However, this decision should be individualized based on the patient's risk for severe COVID-19 illness 1.
The evidence shows that while revaccination may be considered in those with chest pain not meeting criteria for pericarditis, caution is warranted in adults with confirmed myopericarditis, as recurrence has been documented 5.